Drugs / Autologous Natural Killer Cell-like CTLs
Autologous Natural Killer Cell-like CTLs
Trials 1 · a red edge is where a trial was stopped
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1/2 | NCT03735589 | Dec 2023 → Dec 2025 | fallopian tube cancer, primary peritoneal carcinoma, uterine adnexa cancer | Roswell Park Cancer Institute | Withdrawn | No outcome recorded |
Evidence & citations 4 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | Autologous Natural Killer Cell-like CTLs | ClinicalTrials.gov intervention name — accepted as the source's own label NCT03735589 ↗ |
| Action | Deplete | “how to recognize and eliminate tumor cells” NCT03735589 ↗ |
| Modality | Cell therapy | “natural killer cell-like cytotoxic T-lymphocytes (CTLs) (nCTLs)” NCT03735589 ↗ |
| Route | Other | “Given IP” NCT03735589 ↗ |